New Delhi-based Mankind Pharma has announced a strategic partnership with the Lepra Society to launch a comprehensive initiative aimed at eradicating, raising awareness, and treating leprosy.

Under their corporate social responsibility (CSR) arm, the company is committed to making a meaningful impact in regions affected by leprosy, and as part of this commitment, they have established five exclusive Comprehensive Disability Care Centers (CDCC) across different locations.

The CDCCs are strategically positioned in regions identified as high-impact areas, including the NTR District in Andhra Pradesh, Guru Gobind Hospital in Delhi, the Government Hospital in Chandarpur, Maharashtra, the Community Care Centre in Odisha, Koraput, and Nirmal District in Telangana. These centres are operational throughout the year, addressing various issues related to leprosy and elephantiasis. The company aims to provide essential treatment and raise awareness through these centres, collaborating closely with the Lepra Society.

Mankind Pharma will undertake a range of vital activities to combat leprosy and its socio-economic impacts. Over 80,000 individuals will undergo comprehensive screening, accompanied by extensive awareness programmes designed to educate and inform communities. Additionally, the initiative aims to provide treatment to more than 6,000 patients through the morbidity management and disability program, showcasing the commitment to holistic care. Over 10 reconstructive surgeries are slated to take place, aimed at restoring normalcy for affected individuals.